Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Pullback support levels are at $84.06, $80.78, $78.07, and $73.25. Moderna reported a Q2 2024 EPS loss of $3.33, beating consensus estimates for a loss of $3.35 by 2 cents. GAAP net loss was $1.3 ...

Simply Good Foods Company will report Q2 financial results on July 10, 2025, with a conference call scheduled for 6:30 a.m. MT.

Beta Bionics plans to announce Q2 2025 financial results on July 29, followed by a conference call.

Moderna’s shares rallied after the biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial. In early trading, the shares were 4.3% higher at ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent ...

Trade talks ahead of July 9 cut-off, Netanyahu meets US president and UK Post Office IT scandal inquiry publishes its first ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010 ...